2016 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/12/16Exicure Enters Into a Strategic Alliance with Purdue Pharma L.P.
... 
Printer Friendly Version
10/11/16Exicure Announces Positive Phase 1 Data for Topical Anti-TNF Compound AST-005 in Patients with Mild to Moderate Psoriasis
SKOKIE, Ill., Oct. 11, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced results from the Phase 1 clinical trial of its compound, AST-005, a SNA designed to reduce the expression tumor necrosis factor messenger RNA (TNF mRNA). TNF is a central driver of psoriasis. The trial evaluated the safety, tolerability, and disease-related biomarkers in chronic plaque psoriasis patients follo... 
Printer Friendly Version
04/26/16Exicure Announces Dosing of First Patient in Phase 1 Trial for the Treatment of Chronic Plaque Psoriasis
SKOKIE, Ill., April 26, 2016 (GLOBE NEWSWIRE) -- Exicure, a pioneer in developing Spherical Nucleic Acid (SNA™) constructs as gene regulatory and immunotherapeutic agents, today announced the dosing of the first patient in a Phase 1 trial of its AST-005 gel for chronic plaque psoriasis, an inflammatory disease that results in red, scaly patches on the skin. Current treatments for psoriasis are limited to biologics, which are generally administered systemically, orally administered drugs and a... 
Printer Friendly Version
02/12/16Exicure Co-Founder Awarded Prestigious Dan David Prize
SKOKIE, Ill., Feb. 12, 2016 (GLOBE NEWSWIRE) -- Exicure is pleased to announce that Chad A. Mirkin, Ph.D., co-founder and director of Exicure, has been named the recipient of the 2016 Dan David Prize in the Future Time Dimension. Dr. Mirkin is being awarded the prize for his ground-breaking contributions to the field of nanoscience. His work led to the invention of 3-D structures called spherical nucleic acids (SNAs) which are currently being developed by Exicure. The prize will be presented o... 
Printer Friendly Version

Print Page  | E-mail Page  | RSS Feeds  | E-mail Alerts  | IR Contacts  | Financial Tear Sheet